No results were found for the filter!
NEW
pS417/pS419-CCK1 (phospho-Cholecystokinin... Serine417/Serine419 (S417/S419) is a major phosphorylation site of the CCK1 receptor. The pS417/pS419-CCK1 antibody detects phosphorylation in response to high-efficacy agonists. S417/S419 phosphorylation is a key regulator of CCK1...
$ 375.00 *
NEW
pS412/pS414-CCK1 (phospho-Cholecystokinin... Serine412/Serine414 (S412/S414) is a major phosphorylation site of the CCK1 receptor. The pS412/pS414-CCK1 antibody detects phosphorylation in response to high-efficacy agonists. S412/S414 phosphorylation is a key regulator of CCK1...
$ 375.00 *
NEW
pT408/pT409-CCK1 (phospho-Cholecystokinin... Threonine408/Threonine409 (T408/T409) is a major phosphorylation site of the CCK1 receptor. The pT408/pT409-CCK1 antibody detects phosphorylation in response to high-efficacy agonists. T408/T409 phosphorylation is a key regulator of CCK1...
$ 375.00 *
Citations
CCK1 (non-phospho), Cholecystokinin Receptor 1... The CCK1 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Cholecystokinin Receptor 1 (previously called CCKA). It can be used to detect total CCK1 receptors in Western blots independent of...
$ 375.00 *
Citations
CCK1 (IHC-grade), Cholecystokinin Receptor 1... The CCK1 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Cholecystokinin Receptor 1 (previously called CCKA). It can be used to detect total CCK1 receptors in Western blots independent of...
$ 375.00 *
Recently viewed
The cholecystokinin type 1 receptor (CCK₁), formerly known as CCK-A and encoded by CCKAR, is a class A G protein-coupled receptor that responds preferentially to sulfated forms of cholecystokinin (CCK). It couples predominantly to Gq/11, activating phospholipase C and increasing intracellular calcium. CCK₁ is expressed in gallbladder smooth muscle, the gastrointestinal tract, and vagal afferent neurons. Dietary fats and proteins stimulate intestinal CCK release, and activation of CCK₁ promotes gallbladder contraction and pancreatic enzyme secretion. CCK₁ signaling in vagal afferents also slows gastric emptying and contributes to meal-induced satiation. Agonist exposure can induce receptor phosphorylation, desensitization, and internalization, limiting responsiveness during sustained stimulation. The synthetic sulfated CCK octapeptide sincalide is approved in the United States for diagnostic use, including stimulation of gallbladder contraction during hepatobiliary imaging. The selective CCK₁ antagonist dexloxiglumide has been evaluated in clinical trials for irritable bowel syndrome. CCK1 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal threonine408/threonine409 (pT408/pT409-CCK1), serine412/serine414 (pS412/pS414-CCK1) and serine417/serine419 (pS417/pS419-CCK1). This nomenclature refers to the human CCK1. This phosphorylation motif is conserved across species but corresponds to pT416-CCK1, pS420/pS422-CCK1 and pS425/pS427-CCK1 in mice. For more information on CCK1 pharmacology please refer to the